What Is the FDA 503A Bulks List?

What the 503A bulks list actually is

When most people picture a medication, they picture a finished product: an approved drug in a sealed, labeled package. Compounding pharmacies work differently. They combine or alter ingredients to make a customized preparation, and to do that they often start from a raw active pharmaceutical ingredient — the pure powder of the drug substance itself. In regulatory language that raw ingredient is a bulk drug substance. The 503A bulks list is the FDA's evolving catalog of which bulk substances a traditional compounding pharmacy is allowed to use when the substance is not otherwise covered by existing rules.

The name comes from Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act, the part of federal law that governs traditional pharmacy compounding for individual patients. The list matters enormously for the peptide world because nearly every research peptide — from BPC-157 to TB-500 — is exactly the kind of substance that has no approved finished product and no long-standing pharmacopeial recognition. Whether such a substance can be compounded at all comes down to how it is treated on this list.

The three lawful sourcing paths under 503A

Section 503A does not let a pharmacy compound from just any raw ingredient. For a bulk drug substance to be eligible, it must satisfy at least one of three conditions written into the statute. Understanding these three paths is the fastest way to understand why peptides are treated the way they are.

1. It appears on the FDA 503A bulks list. The substance has been formally reviewed (or is under review) and permitted for compounding under the interim policy.
2. It is the subject of an applicable USP or NF monograph. The United States Pharmacopeia (USP) or National Formulary (NF) has published an official quality standard — an identity, strength, and purity specification — for the substance.
3. It is a component of an FDA-approved drug. The bulk substance is already the active ingredient in a product the FDA has approved, so its identity and quality are established.

The problem for most research peptides is that they satisfy none of the three. They are not components of any FDA-approved drug, the USP has not published monographs for them, and — critically — when they were reviewed for the bulks list, they were not permitted. That triple gap is what leaves peptides with no lawful compounding route. To see how this plays out for one substance in detail, read can compounding pharmacies compound BPC-157?.

Where the framework came from: the DQSA of 2013

The modern compounding framework did not appear by accident. It was Congress's response to a 2012 public-health disaster in which contaminated compounded injections caused a multistate outbreak, killing dozens of people and sickening hundreds. That tragedy exposed a gap: large-scale compounding had grown far beyond the traditional model of a pharmacist filling a single prescription, yet oversight had not kept pace.

In 2013, Congress passed the Drug Quality and Security Act (DQSA). It clarified and strengthened FDA oversight of compounding by defining two distinct lanes under the FD&C Act — Section 503A for traditional, patient-specific compounding, and Section 503B for a new category of larger "outsourcing facilities." The DQSA also set up the interim process by which nominated bulk drug substances are evaluated and sorted into categories while the FDA works through formal rulemaking. That interim category system is the backbone of everything discussed here.

In short: the bulks list exists because Congress decided that compounding from raw substances needed a documented, safety-driven gatekeeping process. Peptides simply happen to be a class of substances that, when run through that process, largely did not clear the bar.

How the nomination process works

A substance does not appear on the 503A bulks list on its own. Someone — often a compounding pharmacy, a trade organization, or another interested party — must nominate it, submitting information the FDA can review. The agency evaluates each nominated substance against factors laid out in its guidance: the physical and chemical characterization of the substance, the safety and effectiveness evidence supporting its use in compounding, any history of use, and whether there is a demonstrated need that approved products cannot meet.

• Nomination. An interested party submits the substance with supporting data to the relevant FDA docket.
• Review. The FDA (with input from its Pharmacy Compounding Advisory Committee) evaluates characterization, safety, effectiveness, and need.
• Interim categorization. While formal rulemaking is pending, the substance is placed into an interim category that signals whether it may be used.
• Final rule. Eventually the FDA codifies decisions through notice-and-comment rulemaking, moving substances onto or off the permanent list.

The interim categories are the part that matters day to day, because final rulemaking is slow. A substance's practical fate — compoundable or not — usually turns on whether the FDA placed it in Category 1 or Category 2. That distinction is important enough to deserve its own section.

Category 1 vs Category 2: what each means in practice

The interim policy sorts nominated bulk substances into two working buckets. The labels sound bureaucratic, but the difference is decisive: one lets compounding continue during review, the other effectively stops it.

• Category 1 — substances that do not appear to raise significant safety risks and for which the nomination included sufficient supporting information. The FDA does not intend to take action against compounding these while it completes its evaluation.
• Category 2 — substances the FDA has identified as raising significant safety concerns, or for which the record is inadequate. These should not be used in compounding during the review period.

The takeaway is blunt: Category 1 keeps a door open; Category 2 closes it. For a substance to have any lawful compounded supply while the FDA deliberates, it needs to be in Category 1 (or otherwise satisfy one of the three sourcing paths). Almost all popular research peptides are in Category 2, which is the root cause of their unusual market.

503A vs 503B: two different kinds of compounding

People often blur "compounding" into a single idea, but the DQSA created two separate lanes with very different rules. Section 503A governs the traditional model: a pharmacy compounds a preparation for an individual patient pursuant to a valid prescription. Section 503B governs outsourcing facilities — larger operations that can compound in bulk without patient-specific prescriptions but must register with the FDA and follow current good manufacturing practice (CGMP), much like a manufacturer.

The two lanes even use different bulk substance lists. A 503B outsourcing facility works from its own bulks list under Section 503B, which is evaluated separately from the 503A list. A substance's status can therefore differ between the two frameworks, though for the major research peptides the practical answer has been the same: no lawful compounded supply.

For a fuller comparison of compounded products versus finished, approved medicines, see research peptides vs prescription peptides and our overview of FDA-approved peptides.

Why so many peptides landed in Category 2

Between roughly 2020 and 2024, the FDA worked through a wave of peptide nominations and placed many of the most popular research peptides in Category 2. The agency's stated reasoning generally clustered around a few recurring concerns: incomplete physical and chemical characterization, limited safety data in humans, questions about immunogenicity (the potential for a peptide to trigger unwanted immune responses), and uncertainty about how the substances are manufactured and purified in the research-chemical supply chain.

It is worth being precise about what Category 2 does and does not say. It is not a criminal schedule, and it is not a declaration that a substance is definitively dangerous. It is a statement that, based on the record before the FDA, the agency has significant safety concerns and does not consider the substance appropriate for compounding during review. That nuance is often lost in online discussion. For the science behind one heavily studied example, see the BPC-157 mechanism overview and the cited BPC-157 research library.

Because these peptides are in Category 2 and satisfy none of the other sourcing paths, there is no lawful compounded channel for them, and no approved finished product either. That vacuum is exactly why they are sold for research use only — a distinction unpacked in why peptides are research-only. It is also why the legal analysis for individual peptides, such as is BPC-157 legal in 2026? and is TB-500 legal in 2026?, keeps returning to this one list.

The semaglutide and tirzepatide shortage exception

The GLP-1 weight-management drugs — semaglutide and tirzepatide — are a useful contrast because they show how the compounding rules bend around drug shortages. Both are the active ingredients in FDA-approved products, so they are not in the same regulatory position as research peptides. When demand outstripped supply and the FDA formally declared shortages, federal law opened a temporary window in which compounders could prepare these substances to help meet patient need.

That window was always conditional. Once the FDA determined the shortages were resolved in early 2025, the temporary permission wound down and compounding of those substances was restricted again. The episode is a clean illustration of a general principle: compounding eligibility is not a permanent property of a molecule — it depends on approval status, list placement, and, in shortage situations, the FDA's active determinations.

The July 2026 advisory committee review

On April 15, 2026, the FDA announced it would convene an advisory committee to reconsider the compounding restrictions on several peptides currently sitting in Category 2. That meeting is scheduled for July 23, 2026. As of this writing, it is an upcoming event, not a completed decision — and it is important to be exact about what an advisory committee can and cannot do.

An advisory committee reviews evidence and issues a non-binding recommendation. The FDA is not required to adopt it. Even a recommendation favorable to compounding would then have to move through the agency's own process, which takes months and, for a permanent change, formal rulemaking. In other words, the July 2026 meeting is a step in a long process, not a switch that flips a peptide from Category 2 to legally compoundable overnight.

We track the meeting and its stakes in detail in the FDA peptide update for July 2026, explain the mechanics of the process in what happens after an FDA advisory committee vote, and place it in the broader story in the FDA peptide ban reversal explainer.